Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR566658 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SAR566658 | EXPERIMENTAL | SAR566658 will be administered by intravenous (IV) infusion according to three different schedules |
| Name | Type | Description |
|---|---|---|
| SAR566658 | DRUG | Pharmaceutical form:solution for infusion Route of administration: intravenous |
Inclusion criteria: Diagnosis of CA6-positive solid tumors as moderate to intense membrane staining of ≥15% of tumor cells for which no standard therapy is available. Exclusion criteria: * Eastem Cooperative Oncology Group performance status ≥2. * Any serious active disease or co-morbid condition...
SAR566658 is an investigational oncology drug studied in patients with CA6-positive refractory solid tumors, including malignant neoplasms. It was evaluated in a single Phase 1 first-in-man study of 114 patients across the United States, France, and Spain. It is not an approved therapy and remains in clinical development.
SAR566658 is a small molecule inhibitor that targets tubulin proteins, specifically TUBB4B, TUBB1, TUBA3C, TUBA4A, TUBB3, and TUBA1A. By binding these tubulin subunits, it interferes with microtubule function in tumor cells. This target class places it among tubulin inhibitor chemotherapies.
SAR566658 is developed by Sanofi, which trades on the New York Stock Exchange under the ticker SNY. Sanofi sponsored the Phase 1 first-in-man trial of the drug in patients with CA6-positive refractory solid tumors.
SAR566658 is in Phase 1 development. Its only recorded clinical trial, NCT01156870, was a Phase 1 first-in-man study that has completed. The drug is investigational and has not been approved by the FDA for any indication.
SAR566658 was studied in NCT01156870, titled First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor. This completed Phase 1 trial enrolled 114 patients aged 18 and older in the United States, France, and Spain. It was an uncontrolled, open-label study.